bioRxivPharmacology & ToxicologyPreprint
Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis
Abstract
We set out to determine if our anti-sepsis drug candidate Rejuveinix (RJX) can effectively treat systemic inflammation in a mouse model of sepsis when used at a dose level that is >10-times lower than its maximum tolerated dose (MTD) for human subjects. Our findings obtained in the LPS-GalN mouse model of fatal sepsis provide experimental evidence that RJX exhibits potent single-agent anti-inflammatory activity and reverses very severe inflammatory lung injury when used therapeutically, thereby significantly improving the survival outcome. These findings demonstrate the clinical impact potential of RJX for the treatment of severe sepsis.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain of Mice: Clinical Impact Potential in COVID-19 and Nervous System Disorders
- Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix
- Circulating Microvesicle-Associated Inducible Nitric Oxide Synthase Is a Novel Therapeutic Target to Treat Sepsis: Current Status and Future Considerations
R. J. Webber, R. M. Sweet, D. S. Webber·bioRxiv·Nov 8, 2021
- Rescuable effect of R-salbutamol in LPS-induced immune dysfunction of sepsis
- Azithromycin reduces systemic inflammation and provides survival benefit in murine model of polymicrobial sepsis
- Long-term immune reprogramming of classical monocytes with altered ontogeny mediates enhanced lung injury in sepsis survivors
Scott J. Denstaedt, Breanna McBean, … Rachel L. Zemans·JCI InsightPeer-reviewed·Sep 24, 2026